Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding (OCCLUDE-II)
PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding - OCCLUDE II
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Prospective, non-randomized, multi-center confirmatory observational study for the treatment of subjects with the need for vascular occlusion for the following conditions:
- Stopping blood loss from a damaged blood vessel from a traumatic vascular injury
- Hemorrhage caused by a neoplasia
- Neoplastic process (tumor)
- Gastrointestinal bleeding
- Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous malformations or an arteriovenous fistula
- Interrupting blood supply to an organ or part of an organ for permanent devascularization
- Devascularization of tissues involved by a neoplastic process either pre-operatively or as a palliative measure
- Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Leon Rudakov, PhD
- Phone Number: +1 (760) 471-7700
- Email: leonrudakov@artventivemedical.com
Study Locations
-
-
-
Klagenfurt, Austria
- Recruiting
- Klinikum Klagenfurt Am Worthersee
-
Contact:
- Klaus Hausegger, Prof. Dr.
- Phone Number: +43 463 538 38 503
- Email: Klaus.hausegger@kabeg.at
-
Linz, Austria
- Not yet recruiting
- Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.
-
Contact:
- Peter Waldenberger, Prof Dr
- Phone Number: +43 73276777346
- Email: Peter.waldenberger@bhs.at
-
Principal Investigator:
- Peter Waldenberger, Prof Dr
-
-
-
-
-
Leuven, Belgium
- Not yet recruiting
- UZ Leuven
-
Contact:
- Geert Maleux, Prof Dr
- Phone Number: +32 16 34 37 82
- Email: geert.maleux@uzleuven.be
-
Principal Investigator:
- Geert Maleux, Prof Dr
-
-
-
-
-
Dresden, Germany
- Not yet recruiting
- Universitatsklinikum Carl Gustav Carus Institut
-
Contact:
- Ralf Hoffmann, PD Dr.
- Phone Number: +49 351 - 458 2259
- Email: radiologie@uniklinikum--dresden.de
-
Principal Investigator:
- Ralf Hoffmann, PD Dr.
-
Leipzig, Germany
- Not yet recruiting
- Universität Leipzig - Department für Bildgebung und Strahlenmedizin
-
Contact:
- Michael Moche, Dr.
- Phone Number: +49 341 9717558
- Email: Michael.moche@medizin.uni-leipzig.de
-
Marburg, Germany
- Not yet recruiting
- Universitätsklinikum Giessen und Marburg (UKGM) Klinik für diagnostische und
-
Contact:
- Andreas Mahnken, Prof Dr
- Phone Number: +49 6421 58-66231
- Email: m.treitl@med.unimuenchen.de
-
Principal Investigator:
- Andreas Mahnken, Prof Dr
-
Munich, Germany
- Not yet recruiting
- LMU Klinikum der Universität München, Campus Innenstadt, Interventionelle Radiologie
-
Contact:
- Marcus Treitl, Prof dr
- Phone Number: +49 89-5160-9271
- Email: m.treitl@med.unimuenchen.de
-
Principal Investigator:
- Marcus Treitl, Prof Dr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Subjects requiring permanent occlusion of the peripheral vessels for the following conditions:
- Stopping blood loss from a damaged blood vessel from a traumatic vascular injury
- Hemorrhage caused by a neoplasia
- Neoplastic process (tumor)
- Gastrointestinal bleeding
- Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous malformations or an arteriovenous fistula
- Interrupting blood supply to an organ or part of an organ for permanent devascularization
- Devascularization of tissues involved by a neoplastic process either pre-operatively or as a palliative measure.
- Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description
Inclusion Criteria:
- Subjects aged ≥18 to ≤75 years.
- Subject with target vessels of 3.0 mm to 12 mm in diameter.
- Subject is able and willing to comply with all study requirements, including the required study follow-up visits.
- Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the consent form. In the event of emergency procedure and subject and/or legal representative is unable to provide consent prior to study enrollment, consent will be obtained at earliest possible time following procedure for consent to continue to participate in the study.
Exclusion Criteria:
- Subject has a known allergy to iodinated contrast for which they cannot be adequately premedicated.
- Subjects in whom venography or arteriography is contraindicated.
- Subjects with known hypersensitivity or contraindication to nickel or nitinol.
- Subject is pregnant or breastfeeding.
- Any clinical evidence that the investigator feels would place the subject at increased risk with the deployment of the device.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: Acute & 30 days
|
Composite of new-onset major device-related adverse event(s) including device embolization beyond targeted treatment area (not therapeutic indication of embolization), need for emergency surgical intervention of the target vessel, or distal embolization (non-device embolization, e.g., particulate matter / plague distal to the device) at 30 days.
|
Acute & 30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occlusion
Time Frame: 30 days
|
Sustained occlusion at 30 days follow-up.
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andreas Mahnken, Prof Dr, Universitätsklinikum Giessen und Marburg (UKGM) Klinik für diagnostische und
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TD 0088 / 04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.